S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

Conditions

• Lymphoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• rituximab — BIOLOGICAL
• cyclophosphamide — DRUG
• doxorubicin hydrochloride — DRUG
• prednisone — DRUG
• vincristine sulfate — DRUG
• R-CHOP regimen — OTHER
• laboratory biomarker analysis — OTHER
• fludeoxyglucose F 18 — RADIATION
• selective external radiation therapy — RADIATION
• yttrium Y 90 ibritumomab tiuxetan — RADIATION

Study Details

RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Comparing results of diagnostic procedures, such as PET scan and CT scan, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase II trial studies how well PET-directed chemotherapy works in treating patients with limited-stage diffuse large B-cell lymphoma.

Key Dates

Start date

Sep 30, 2011

Status verified

May 2025

Primary completion

Jun 3, 2020

Completion

Dec 31, 2023

Study Design

Enrollment

159 participants (actual)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Active Comparator: PET Negative: R-CHOP
  R-CHOP x 3 Cycles
• Experimental: PET Positive: IFRT +Zevalin
  Standard IFRT+ Zevalin IV per ABW

Primary Outcome Measure

Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) [ Time Frame: up to 5 years ]

Locations (240)

Find similar trials in Anchorage, AK

Related Studies

• Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
  Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
• 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
  Recruiting · Barbara Ann Karmanos Cancer Institute · Detroit, Michigan
• Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
  Recruiting · UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina
• Registry of Older Patients With Cancer
  Recruiting · UNC Lineberger Comprehensive Cancer Center · Boone, North Carolina